Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularizations Associated with Pathologic Myopia: A Prospective Study

Pasyechnikova, N.; Науменко, В.; Korol, A.; Zadorozhnyy, O.; Kustryn, Taras; Henrich, P. B.

doi:10.1159/000369397

Cited by 9 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reported elsewhere [31] , the mean CMT was reduced after anti-VEGF treatment. Final CNV lesion size was only associated with baseline CNV lesion size ( p < 0.001).…”

Section: Discussionsupporting

confidence: 84%

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

et al. 2017

View full text Add to dashboard Cite

Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization. Methods: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN). Results: The mean follow-up was 53 ± 16 months. The visual acuities were 51.9 ± 16.2 letters with 3+ PRN and 53 ± 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 ± 12.3 and 69 ± 15.1 letters, respectively, at 12 months; and 67.1 ± 16.2 and 66.4 ± 19.7 letters, respectively, at the end of follow-up (p = 0.877). Mean survival until first retreatment after the loading dose was 36.9 ± 6.1 months with 3+ PRN and 19.2 ± 5.4 months with 1+ PRN (p < 0.001). Conclusions: Both dosing regimens led to similar visual outcomes. For eyes given a single injection in the first quarter, retreatment was needed appreciably earlier.

show abstract

“…As reported elsewhere [31] , the mean CMT was reduced after anti-VEGF treatment. Final CNV lesion size was only associated with baseline CNV lesion size ( p < 0.001).…”

Section: Discussionsupporting

confidence: 84%

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Indeed, the 1-year results from the VIEW 1 and VIEW 2 studies showed that in the treatment of CNV due to AMD, aflibercept was non-inferior under similar dosing regimens to ranibizumab. 24 , 25 , 26 , 27 , 28 Here, aflibercept maintained the visual gains obtained in the first year of the study with significantly fewer injections compared with ranibizumab.…”

Section: Discussionmentioning

confidence: 62%

“…This factor, in conjunction with treatment-related cumulative damage to the photoreceptors and the underlying retinal pigment epithelium, might compromise the long-term results, as underlined by the relatively few aflibercept injections needed in the present study. Several studies 24 , 25 , 26 , 27 and an open-label, non-comparative phase II trial known as REPAIR (Ranibizumab for the trEatmentof CNV secondary to pathological myopia; an Individualised Regimen) 28 , 29 have shown beneficial results of intravitreal ranibizumab for myopic CNV. Twelve-month data from the phase II study indicated that ranibizumab was associated with significant improvements of BCVA score and central macular thickness.…”

Section: Discussionmentioning

confidence: 99%

Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study

Bruè

Pazzaglia

Mariotti

et al. 2015

Eye

View full text Add to dashboard Cite

AimThe aim of this study is to evaluate long-term efficacy of intravitreal injections of aflibercept as primary treatment for subfoveal/juxtafoveal myopic choroidal neovascularisation (CNV).MethodsThirty-eight treatment-naive eyes of thirty-eight patients with subfoveal/juxtafoveal myopic CNV received initial intravitreal aflibercept injections and were followed for at least 18 months. Aflibercept was applied again for persistent or recurrent CNV, as required. Statistical analysis was carried out using SPSS.ResultsMean patient age was 45.8 years, and mean eye refractive error was −7.79 D. For the total patient group (n=38 eyes), mean logMAR best-corrected visual acuity (BCVA) significantly improved from 0.69 at baseline to 0.15 at 18 months (P<0.01). Over half of the treated eyes obtained resolution with one aflibercept injection. Patients were also grouped according to age, as <50 years (n=20 eyes) and ≥50 years (n=18 eyes). Mean BCVA improvement was significantly greater in eyes of the younger myopic CNV group, compared with those of ≥50 years (0.21 vs 0.35; P<0.05). The mean number of aflibercept injections was 1.8 for the <50 years myopic CNV group, and 3.6 for the ≥50 years myopic CNV group (P<0.001). Correlation between spherical equivalent refraction and final visual acuity reached statistical significance only for the <50 years myopic CNV group (P<0.001; Levene's correlation).ConclusionsIntravitreal aflibercept provides long-term visual acuity improvement in myopic CNV. The <50 years old myopic CNV group had significantly fewer injections, with greater visual acuity improvement. Intravitreal aflibercept in myopic CNV does not require the three-injection loading phase used for aflibercept treatment of neovascular age-related macular degeneration.

show abstract

“…Vascular endothelial growth factor regulates angiogenesis and vascular permeability and plays a key role in the pathogenesis of diabetic retinopathy and other retinal vascular disorders [9,19]. Anti-VEGF agents have been successfully used for neovascularization regression and reduction of macular edema, especially in the treatment of intraocular hemorrhage, subretinal neovascular membrane and diabetic macular edema [10,20].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy

Ponomarchuk¹,

Korol²,

Umanets³

2022

Oftalmol Zh

View full text Add to dashboard Cite

Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.

show abstract

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularizations Associated with Pathologic Myopia: A Prospective Study

Cited by 9 publications

References 25 publications

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization

Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study

Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy

Contact Info

Product

Resources

About